AAFM Dermatology Practice Test 2026 – Complete Exam Prep

The association of cutaneous atrophy with the use of steroids in keloid treatment is well-documented and reflects a significant concern when employing this therapeutic approach. Steroids, particularly in the form of intralesional injections, are frequently used to reduce inflammation and scar formation in keloids. However, one of the side effects of topical or injected steroids is that they can lead to thinning of the skin, a condition known as atrophy.

This occurs as steroids can inhibit protein synthesis and collagen formation, which are essential for maintaining the structural integrity of the skin. As a result, prolonged use of steroids in the treatment of keloids can compromise the skin's thickness and strength, making it more susceptible to damage and potentially leading to other complications.

In contrast, while the other options may have some relevance to steroid treatment, their incidence is generally lower than that of cutaneous atrophy. Infection can occur, but the risk is not as directly attributable to steroid use as atrophy. Hypertrophy is the opposite of the desired effect, and allergic reactions can happen but are relatively uncommon in the context of steroid use in keloid treatment. Thus, the potential for cutaneous atrophy stands out as a primary risk associated with steroid therapy in